Arcus Biosciences (RCUS) EBITDA (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly EBITDA of -$134.0 million for Q1 2026, down 9.84% year-over-year from -$148.6 million in Q1 2025, and down 17.54% quarter-over-quarter from -$114.0 million in Q4 2025.
Arcus Biosciences (RCUS) EBITDA (2017 - 2026) Analysis & Trends
Arcus Biosciences' EBITDA history runs 10 years deep, the most recent figure standing at -$134.0 million for Q1 2026.
- In Q1 2026, EBITDA fell 9.84% year-over-year to -$134.0 million; the TTM figure through Mar 2026 stood at -$398.0 million (up 8.72% YoY), while the FY2025 annual figure was -$386.0 million, down 16.97% from the prior year.
- EBITDA for Q1 2026 stood at -$134.0 million, down from -$114.0 million in the prior quarter.
- The five-year high for EBITDA was -$8.0 million in Q2 2025, with the low at -$142.0 million in Q3 2025.
- The 5-year median for EBITDA is -$86.0 million (2023), against an average of -$86.5 million.
- Peak annual rise in EBITDA reached 92.45% in 2025, while the deepest fall reached 662.5% in 2025.
- Arcus Biosciences' EBITDA stood at -$74.0 million in 2022, then decreased by 22.97% to -$91.0 million in 2023, then slipped by 13.19% to -$103.0 million in 2024, then dropped by 10.68% to -$114.0 million in 2025, then decreased by 17.54% to -$134.0 million in 2026.
- Business Quant data shows RCUS's EBITDA at -$134.0 million in Q1 2026, -$114.0 million in Q4 2025, and -$142.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | -96.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -96.00 Mn |
| Mar 31, 2026 | -134.00 Mn |
| Dec 31, 2025 | -114.00 Mn |
| Sep 30, 2025 | -142.00 Mn |
| Jun 30, 2025 | -8.00 Mn |
| Mar 31, 2025 | -122.00 Mn |
| Dec 31, 2024 | -103.00 Mn |
| Sep 30, 2024 | -105.00 Mn |
| Jun 30, 2024 | -106.00 Mn |
| Mar 31, 2024 | -16.00 Mn |
| Dec 31, 2023 | -91.00 Mn |
| Sep 30, 2023 | -80.00 Mn |
| Jun 30, 2023 | -83.00 Mn |
| Mar 31, 2023 | -86.00 Mn |
| Dec 31, 2022 | -74.00 Mn |
| Sep 30, 2022 | -70.00 Mn |
| Jun 30, 2022 | -69.00 Mn |
| Mar 31, 2022 | -67.00 Mn |
| Dec 31, 2021 | 281.02 Mn |
| Sep 30, 2021 | -78.14 Mn |